Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bromocriptine for Peripartum Cardiomyopathy
NCT00998556Phase 2Completed
- Sponsor
- Hannover Medical School
- Start
- Jun 2010
- Primary completion
- Mar 2016
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bromocriptine in Peripartum cardiomyopathy (PPCM) (2 arms), sponsored by Hannover Medical School. Primary endpoint: Change in left ventricular ejection fraction from baseline to six months follow-up at 6 months. Started Jun 2010; status: completed.
02
Drugs
bromocriptine
03
Conditions
Peripartum cardiomyopathy (PPCM)
Beyond the preview
Go deeper on NCT00998556.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00998556.